

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 10, 2024

COHERUS BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-36721
(Commission
File Number)

27-3615821
(IRS Employer
Identification Number)

333 Twin Dolphin Drive, Suite 600
Redwood City, CA 94065
(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (650) 649-3530

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	CHRS	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On January 10, 2024, Coherus BioSciences, Inc. (the "Company") will present its preliminary unaudited revenue for the fiscal year ended December 31, 2023 in a public webcast presentation at the 42nd Annual J.P. Morgan Healthcare Conference. A copy of the preliminary financial information included in such presentation is furnished as Exhibit 99.1 to this report and will be available on the Company's investor relations website at www.investors.coherus.com as previously announced.

Cautionary Note Regarding Preliminary Unaudited Financial Results

The Company is providing the preliminary financial information for the quarter and fiscal year ended December 31, 2023 based on currently available information. The Company's financial closing procedures for the quarter and fiscal year ended December 31, 2023 are not yet complete. These procedures may result in changes that could significantly affect such preliminary unaudited results. As a result, the Company's final results for the quarter and year ended December 31, 2023 may vary materially from the preliminary unaudited results furnished in Exhibit 99.1. The Company's independent registered public accounting firm has not reviewed or audited the financial results presented in this announcement.

This information furnished pursuant to this Item 2.02 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Slide dated January 10, 2024
104	Cover page Interactive Data file (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 10, 2024

COHERUS BIOSCIENCES, INC.

By: /s/ Dennis M. Lanfear
Name: Dennis M. Lanfear
Title: President and Chief Executive Officer

2023 Revenue Growth

Quarter over quarter sales growth from Q1 through Q4

- ◆ **2023 Net Revenues** (\$255 - \$260 million) achieved upper end of guidance range
 - ◆ Q4 revenues >\$90M
- ◆ **CIMERLI** – Quarter-over-quarter revenue growth after Q-Code April 2023
- ◆ **UDENYCA** – Quarter-over-quarter net revenue growth
 - ◆ Strong ASP to support Q1 2024 OBI launch
 - ◆ Three presentations provide long term market share increase opportunity
- ◆ **LOQTORZI** –Distributors stocked, patients dosed, sales ramp initiated

The preliminary 2023 financial information presented here has not been reviewed by our auditor or audited and is subject to significant change. We have not completed our financial close process. The completed, audited Coherus Fourth Quarter and Full Year 2023 Financial Results are planned for release in March 2024

